Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Gain reports positive topline results from Phase 1 trial of therapy for Parkinson’s

Gain Therapeutics (NASDAQ:GANX) has announced positive results from its Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson’s...

August 29, 2024

Developments

LIXTE and NKI dose first patient with LB100 in colorectal cancer study supported by Roche

LIXTE Biotechnology (NASDAQ:LIXT) has announced that, in collaboration with the Netherlands Cancer Institute (NKI), the first patient has been dosed in a new clinical trial of LUXTE’s lead compound, LB-100, for the...

August 26, 2024

Developments

Emergent donates 50,000 smallpox vaccine doses in response to WHO’s mpox declaration

Emergent BioSolutions (NYSE:EBS) announced its pledge to donate 50,000 doses of its ACAM2000 smallpox vaccine through Direct Relief in response to WHO’s declaration that the upsurge of mpox in the Democratic Republic of...

August 20, 2024

Developments

Tonix enrolls first patient in Phase 2 study of TX1300 for acute cocaine intoxication

Tonix Pharmaceuticals (NASDAQ:TNXP) announced the first patient dosing in its Phase 2 trial of the recombinant enzyme TNX-1300 for treating life-threatening cocaine intoxication in patients presenting to the emergency...

August 20, 2024

Developments

First participant dosed in Monte Rosa’s Phase 1 study of MRT-6160 for autoimmune disease

Monte Rosa Therapeutics (NASDAQ:GLUE) announced that the first participant has been dosed in its Phase 1 healthy volunteer study evaluating MRT-6160, a VAV1-directed MGB being developed for systemic and neurological...

August 19, 2024

Developments

Optimi Health announces export of first MDMA capsules for PTSD to Australia

Optimi Health (CSE:OPTI; OTCQX:OPTHF; FSE:8BN) reports completion of its inaugural export of GMP-validated, 3,4-methylenedioxymethamphetamine (MDMA) capsules to Australia for the treatment of patients with post...

August 16, 2024

Developments

Perimeter reports progress on several fronts

Perimeter Medical Imaging AI (TSX:PINK; OTC:PYNKF; FSE:4PC) highlighted several positive developments and achievements in its Q2 report and conference call yesterday. Perimeter is a medical technology company working to...

August 15, 2024

Developments

Zomedica partners with SIRE to expand sales into Central America

Zomedica (NYSEA:ZOM) announced the expansion of its sales reach into Costa Rica through a partnership with SIRE Veterinario, which will be the exclusive distributor of Zomedica products in that country. “Our...

August 14, 2024

Developments

FDA accepts scPharmaceuticals sNDA to expand heart failure drug indication

scPharmaceuticals (NASDAQ:SCPH) has announced FDA approval of its supplemental NDA (sNDA) for FUROSCIX, expanding its indication to New York Heart Association (NYHA) Class IV chronic heart failure patients. Previously...

August 12, 2024

Developments

NIH awards grant to Marker Therapeutics through SBIR program

Marker Therapeutics (NASDAQ:MRKR) has announced that it has been awarded a $2 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program to support the clinical...

August 12, 2024

Developments

OneMedNet successfully integrates its proprietary AI technology into its data curation process, boosting efficiency up to 5X

OneMedNet (NASDAQ:ONMD) reported today that it has successfully integrated its proprietary AI technology into its data curation process, ensuring rapid and precise de-identification of patient data. This innovation...

August 9, 2024

Developments

Awakn screens first patient in Phase 3 trial of treatment for AUD

Awakn Life Sciences (CSE:AWKN; OTCQB:AWKNF; FSE:954) has announced that the first patient has been screened in its landmark MORE-KARE Phase 3 trial of AWKN-001, an investigational, novel medication-assisted treatment...

August 9, 2024

Developments

Veru meets full enrollment target in Phase 2b study of Enobosarm for Obesity

Veru (NASDAQ:VERU) announced that it has reached its targeted full enrollment of 150 patients for its Phase 2b QUALITY clinical trial of enobosarm, in combination with semaglutide, aimed at muscle preservation for high...

August 8, 2024

Developments

Rockwell launches ergonomic hemodialysis packaging solution for home patients and acute facilities

Rockwell Medical (NASDAQ:RMTI) announced the launch of a convenience pack including pre-mixed containers of the company’s hemodialysis concentrate products, offering in-home dialysis patients and acute dialysis...

August 8, 2024

Developments

89bio names Francis Sarena as COO

89Bio (NASDAQ:ETNB) announced the appointment of Francis Sarena as chief operating officer, effective August 5, 2024. Mr. Sarena brings 25 years of biotech industry experience to his new role at 89bio. Prior to joining...

August 7, 2024

Developments

Silo partners with global CRO for preclinical study to advance homing peptide in MS

Silo Pharma (NASDAQ:SILO) has entered into an agreement with WuXi AppTec for a preclinical small animal study of SPU-16, a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS). Silo Pharma is...

August 7, 2024

Developments

Quoin Pharma plans clinical study of peeling skin syndrome in children

Quoin Pharmaceuticals (NASDAQ:QNRX) announced plans to initiate an investigator-led clinical study to evaluate the safety and efficacy of QRX003 in pediatric patients with peeling skin syndrome (PSS). The study will be...

August 6, 2024

Developments

Abivax achieves key enrollment milestone in Phase 3 trial of Obefazimod in UC

Abivax SA (Euronext Paris, NASDAQ:ABVX) reports reaching the 600-patient enrollment milestone for its Phase 3 ABTECT trial to evaluate its lead investigational drug candidate, Obefazimod, in patients with moderate-to...

August 6, 2024

Developments

BioResorative’s Chief Scientist named section editor of top-tier Journal of Translational Medicine

BioRestorative Therapies (NASDAQ:BTRX) announced that Francisco Silva, the company’s chief scientist and vice president of research and development, has been appointed section editor of the newly launched Regenerative...

July 23, 2024

Developments

Cytel unveiled as alliance partner with OneMedNet

Closely-held Cytel, a global leader in clinical trial design and software, announced today its strategic partnership with OneMedNet (NASDAQ:ONMD) to enhance data-driven healthcare solutions. The partnership will...

July 22, 2024

Developments

Anebulo announces NIDA grant for investigational treatment of acute cannabis-induced toxicities in children

Anebulo Pharmaceuticals (NASDAQ:ANEB) has been awarded the first tranche of a two-year, $1.9 million NIDA grant to develop intravenous selonabant for treating acute cannabis-induced toxicity, including CNS depression in...

July 22, 2024

Developments

Clearmind files additional U.S. patent application for MEAI to treat obesity

Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced it has filed an additional patent application with the USPTO for the novel proprietary composition of its MEAI compound for treating metabolic syndrome and obesity...

July 16, 2024

Gain reports positive topline results from Phase 1 trial of therapy for Parkinson’s

LIXTE and NKI dose first patient with LB100 in colorectal cancer study supported by Roche

Emergent donates 50,000 smallpox vaccine doses in response to WHO’s mpox declaration

Tonix enrolls first patient in Phase 2 study of TX1300 for acute cocaine intoxication

First participant dosed in Monte Rosa’s Phase 1 study of MRT-6160 for autoimmune disease

Optimi Health announces export of first MDMA capsules for PTSD to Australia

Perimeter reports progress on several fronts

Zomedica partners with SIRE to expand sales into Central America

FDA accepts scPharmaceuticals sNDA to expand heart failure drug indication

NIH awards grant to Marker Therapeutics through SBIR program

OneMedNet successfully integrates its proprietary AI technology into its data curation process, boosting efficiency up to 5X

Awakn screens first patient in Phase 3 trial of treatment for AUD

Veru meets full enrollment target in Phase 2b study of Enobosarm for Obesity

Rockwell launches ergonomic hemodialysis packaging solution for home patients and acute facilities

89bio names Francis Sarena as COO

Silo partners with global CRO for preclinical study to advance homing peptide in MS

Quoin Pharma plans clinical study of peeling skin syndrome in children

Abivax achieves key enrollment milestone in Phase 3 trial of Obefazimod in UC

BioResorative’s Chief Scientist named section editor of top-tier Journal of Translational Medicine

Cytel unveiled as alliance partner with OneMedNet

Anebulo announces NIDA grant for investigational treatment of acute cannabis-induced toxicities in children

Clearmind files additional U.S. patent application for MEAI to treat obesity

General

More